Modulation of intracellular iron metabolism by iron chelation affects chromatin remodeling proteins and corresponding epigenetic modifications in breast cancer cells and increases their sensitivity to chemotherapeutic agents

International Journal of Oncology

Volumn 42, Issue 5, 2013, Pages 1822-1832

  Pogribny, Igor P ^a   Tryndyak, Volodymyr P ^a   Pogribna, Marta ^a   Shpyleva, Svitlana ^a   Surratt, Gordon ^a   Da Costa, Gonçalo Gamboa ^a   Beland, Frederick A ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

Breast cancer; DNA methylation; Histone modifications; Iron metabolism

Indexed keywords

CISPLATIN; DEFEROXAMINE; DOXORUBICIN; HISTONE DEMETHYLASE; HISTONE H3; HISTONE H3 LYSINE 9 DEMETHYLASE; JUMONJI DOMAIN CONTAINING PROTEIN 2A; LYSINE DERIVATIVE; LYSINE SPECIFIC DEMETHYLASE 1; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CHEMOSENSITIVITY; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; DNA MODIFICATION; DOWN REGULATION; DRUG MECHANISM; DRUG SENSITIVITY; EPIGENETICS; GENETIC REGULATION; HUMAN; HUMAN CELL; IRON CHELATION; IRON METABOLISM; PRIORITY JOURNAL; TUMOR GENE; WILD TYPE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CHROMATIN ASSEMBLY AND DISASSEMBLY; CISPLATIN; DOWN-REGULATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; HUMANS; IRON; IRON CHELATING AGENTS; MCF-7 CELLS; UP-REGULATION;

EID: 84876009407     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1855     Document Type: Article

References (46)

1. Teperino R, Schoonjans K and Auwerx J: Histone methyltransferases and demethylases; can they link metabolism and transcription? Cell Metab 12: 321-327, 2010.
2. Burgio G, Onorati MC and Corona DFV: Chromatin remodeling regulation by small molecules and metabolites. Biochim Biophys Acta 1799: 671-680, 2010.
3. Hou H and Yu H: Structural insights into histone lysine demethylation. Curr Opin Struct Biol 20: 739-748, 2010.
4. Iyer LM, Abhiman S and Aravind L: Natural history of eukaryotic DNA methylation systems. Prog Mol Biol Transl Sci 101: 25-104, 2011.
5. Tsukada Y-i, Fang J, Erdjument-Bromage H, Warren ME, Borchers CH, Tempst P and Zhang Y: Histone demethylation by a family of JmjC domain-containing proteins. Nature 439: 811-816, 2006. (Pubitemid 43255695)
6. Yamane K, Toumazou C, Tsukada Y-i, Erdjument-Bromage H, Tempst P, Wong J and Zhang Y: JHDM2A, a JmjC-containing H3K9 demethylase, facilitates transcription activation by androgen receptor. Cell 125: 483-495, 2006.
7. Wu H and Zhang Y: Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation. Genes Dev 25: 2436-2452, 2011.
8. McDonough MA, Loenarz C, Chowdhury R, Clifton IJ and Schofield CJ: Structural studies of human 2-oxoglutarate dependent oxygenases. Curr Opin Struct Biol 20: 659-672, 2010.
9. Torti SV and Torti FM: Ironing out cancer. Cancer Res 71: 1511-1514, 2011.
10. Jones PA, Baylin SB: The epigenomics of cancer. Cell 128: 683-692, 2007. (Pubitemid 46273572)
11. Miller LD, Coffman LG, Chou JW, Black MA, Berg J, D'Agostino R Jr, Torti SV and Torti FM: An iron regulatory gene signature predicts outcome in breast cancer. Cancer Res 71: 6728-6737, 2011.
12. Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell 144: 646-674, 2011.
13. Baylin SB and Jones PA: A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer 11: 726-734, 2011.
14. Buss JL, Torti FM and Torti SV: The role of iron chelation in cancer therapy. Curr Med Chem 10: 1021-1034, 2003. (Pubitemid 36582246)
15. Yu Y, Gutierrez E, Kovacevic Z, Saletta F, Obeidy P, Suryo Rahmanto Y and Richardson DR: Iron chelators for the treatment of cancer. Curr Med Chem 19: 2689-2702, 2012.
16. Kawamoto M, Horibe T, Kohno M and Kawakami K: A novel transferring receptor-targeted hybrid peptide disintegrates cancer cell membrane to induce rapid killing of cancer cells. BMC Cancer 11: 359, 2011.
17. Rao VA, Klein SR, Agama KK, Toyoda E, Adachi N, Pommier Y, and Shacter EB: The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIα in breast cancer cells. Cancer Res 69: 948-957, 2009.
18. Chekhun VF, Lukyanova NY, Kovalchuk O, Tryndyak VP and Pogribny IP: Epigenetic profiling of multidrug-resistant MCF-7 breast cancer adenocarcinoma cells reveals novel hyper- and hypomethylated targets. Mol Cancer Ther 6: 1089-1098, 2007. (Pubitemid 46554580)
19. Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative CT method. Nat Protoc 3: 1101-1108, 2008. (Pubitemid 351818697)
20. Zhang JJ, Zhang L, Zhou K, Ye X, Liu C, Zhang L, Kang J and Cai C: Analysis of global DNA methylation by hydrophilic interaction ultra high-pressure liquid chromatography tandem mass spectrometry. Anal Biochem 413: 164-170, 2011.
21. Pogribny I, Yi P and James SJ: A sensitive new method for rapid detection of abnormal methylation patterns in global DNA and within CpG islands. Biochem Biophys Res Commun 262: 624-628, 1999. (Pubitemid 29443707)
22. Kim TD, Shin S, Berry WL, Oh S and Janknecht R: The JMJDA demethylase regulates apoptosis and proliferation in colon cancer cells. J Cell Biochem 113: 1368-1376, 2012.
23. Stewart MD, Li J and Wong J: Relationship between histone H3 lysine 9 methylation, transcription repression, and heterochromatin protein 1 recruitment. Mol Cell Biol 25: 2525-2538, 2005. (Pubitemid 40381619)
24. Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Casero RA and Shi Y: Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119: 941-953, 2004. (Pubitemid 40037608)
25. Hileti D, Panayiotidis P and Hoffbrand AV: Iron chelators induce apoptosis in proliferating cells. Br J Haematol 89: 181-187, 1995.
26. Pan YJ, Hopkins RG and Loo G: Increased GADD153 gene expression during iron chelation-induced apoptosis in Jurkat T-lymphocytes. Biochim Biophys Acta 1691: 41-50, 2004. (Pubitemid 38410949)
27. So EY, Ausman M, Saeki T and Ouchi T: Phosphorylation of SMC1 by ATR is required for desferrioxamine (DFO)-induced apoptosis. Cell Death Dis 2: e128, 2011.
28. Saletta F, Suryo Rahmanto Y, Siafakas AR and Richardson DR: Cellular iron depletion and the mechanisms involved in the iron-dependent regulation of the growth arrest and DNA damage family of genes. J Biol Chem 286: 35396-35406, 2011.
29. Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, Brady HA, Gandhi AK, Schafer PH, Muller GW, Worland PJ, Chan KW and Verhelle D: Pomalidomide and lenalidomide induce p21WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res 69: 7347-7356, 2009.
30. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
31. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
32. Huang X: Does iron have a role in breast cancer? Lancet Oncol 9: 803-807, 2008. (Pubitemid 352038319)
33. Pinnix ZK, Miller LD, Wang W, D'Agostino R Jr, Kute T, Willngham MC, Hatcher H, Tesfay L, Sui G, Di X, Torti SV and Torti FM: Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med 2: 43ra56, 2010.
34. Shpyleva SI, Tryndyak VP, Kovalchuk O, Starlard-Davenport A, Chekhun VF, Beland FA and Pogribny IP: Role of ferritin alterations in human breast cancer cells. Breast Cancer Res Treat 126: 63-71, 2011.
35. Hoke EM, Maylock CA and Shacter E: Desferal inhibits breast tumor growth and does not interfere with the tumoricidal activity of doxorubicin. Free Radic Biol Med 39: 403-411, 2005. (Pubitemid 40910197)
36. Whitnall M, Howard J, Ponka P, and Richardson DR: A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci USA 103: 14901-14906, 2006. (Pubitemid 44527826)
37. Chen Z, Zhang D, Yue F, Zheng M, Kovacevic Z and Richardson DR: The iron chelators Dp44mT and DFO inhibit TGF-β-induced epithelial-mesenchymal transition via up-regulation of N-Myc downstream-regulated gene-1 (NDRG1). J Biol Chem 287: 17016-17028, 2012.
38. Pollard PJ, Loenarz C, Mole DR, McDonough MA, Gleadle JM, Schofield CJ and Ratcliffe PJ: Regulation of Jumonji-domain-containing histone demethylases by hypoxia-inducible factor (HIF)-1α. Biochem J 416: 387-394, 2008.
39. Culhane JC and Cole PA: LSD1 and the chemistry of histone demethylation. Curr Opin Chem Biol 11: 561-568, 2007. (Pubitemid 47588999)
40. Luka Z, Moss F, Loukachevitch LV, Bornhop DJ and Wagner C: Histone demethylase LSD1 is a folate-binding protein. Biochemistry 50: 4750-4756, 2011.
41. Black JC, Allen A, Van Rechem C, Forbes E, Longworth M, Tschöp K, Rinehart C, Quiton J, Walsh R, Smallwood A, Dyson NJ and Whetstine JR: Conserved antagonism between JMJD2A/KDM4A and HP1γ during cell cycle progression. Mol Cell 40: 736-748, 2010.
42. Mallette FA, Mattiroli F, Cui G, Young LC, Hendzel MJ, Mer G, Sixma TK and Richard S: RNF8- and RNF168-dependent degradation of KDM4A/JMJD2A triggers 53BP1 recruitment to DNA damage sites. EMBO J 31: 1865-1878, 2012.
43. Kim TD, Oh S, Shin S and Janknecht R: Regulation of tumor suppressor p53 and HCT116 cell physiology by histone demethylase JMJD2D/KDM4D. PLoS One 7: e34618, 2012.
44. Binda O, LeRoy G, Bua DJ, Garcia BA, Gozani O and Richard S: Trimethylation of histone H3 lysine 4 impairs methylation of histone H3 lysine 9. Regulation of lysine methyltransferases by physical interaction with their substrates. Epigenetics 5: 767-775, 2010.
45. Kovacevic Z, Sivagurunathan S, Mangs H, Chikhani S, Zhang D and Richardson DR: The metastasis suppressor, N-myc downstream regulated gene 1 (NDRG1), upregulates p21 via p53-independent mechanisms. Carcinogenesis 32: 732-740, 2011.
46. Tryndyak VP, Beland FA and Pogribny IP: E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. Int J Cancer 126: 2575-2583, 2010.